{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:24:22Z","timestamp":1771572262634,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009913","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000}}],"reference-count":69,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009913.pub2","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T12:57:39Z","timestamp":1463489859000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis"],"prefix":"10.1002","volume":"2016","author":[{"given":"Carmen R","family":"Gallardo","sequence":"first","affiliation":[{"name":"Hospital Universitario San Juan de Alicante; Preventive Medicine and Healthcare Quality Service; Ctra. Nacional. 332 Alicante-Valencia, s\/n Alicante Alicante Spain 03550"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rigau Comas","sequence":"additional","affiliation":[{"name":"Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 167 Barcelona Catalonia Spain 08025"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica","family":"Valderrama Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol. Universitat Aut\u00f2noma de Barcelona; Clinical of Pharmacology Department; Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Roqu\u00e9 i Figuls","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 Edifici Casa de Convalesc\u00e8ncia Barcelona Catalunya Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy Anne","family":"Parker","sequence":"additional","affiliation":[{"name":"Universidad Miguel Hern\u00e1ndez de Elche, CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Department of Public Health, History of Science and Gynaecology; Alicante Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Cayl\u00e0","sequence":"additional","affiliation":[{"name":"Ag\u00e8ncia de Salut P\u00fablica de Barcelona, Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Bonfill Cosp","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP) - Universitat Aut\u00f2noma de Barcelona; Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret, 167 Pavilion 18 (D-13) Barcelona Catalunya Spain 08025"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD009913.pub2-BIB0001|cit1","first-page":"760","article-title":"Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis","volume":"13","author":"Bartacek","year":"2009","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"3","key":"10.1002\/14651858.CD009913.pub2-BIB0002|cit2","first-page":"209","article-title":"A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment","volume":"7","author":"Agounitestane","year":"1990","journal-title":"Revue des Maladies Respiratoires"},{"issue":"1","key":"10.1002\/14651858.CD009913.pub2-BIB0003|cit3","first-page":"59","article-title":"Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis","volume":"6","author":"Bellabas","year":"1989","journal-title":"Revue des Maladies Respiratoires"},{"issue":"5","key":"10.1002\/14651858.CD009913.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0962-8479(95)90006-3","article-title":"Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis","volume":"76","author":"Chaulet","year":"1995","journal-title":"Tuberculosis and Lung Disease"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD009913.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0041-3879(87)80021-1","article-title":"United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide","volume":"68","author":"Geiter","year":"1987","journal-title":"Tubercle"},{"issue":"14","key":"10.1002\/14651858.CD009913.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2011.436","article-title":"Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial","volume":"305","author":"Lienhardt","year":"2011","journal-title":"The Journal of the American Medical Association"},{"issue":"10","key":"10.1002\/14651858.CD009913.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.5588\/ijtld.14.0281","article-title":"Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis","volume":"18","author":"Nunn","year":"2014","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"1","key":"10.1002\/14651858.CD009913.pub2-BIB0008|cit8","first-page":"23","article-title":"Considerations about the efficiency of treatment regimens with fixed Rifampicin-Isoniazid combinations in pulmonary tuberculosis","volume":"53","author":"Munteanu","year":"2004","journal-title":"Pneumologia"},{"issue":"2","key":"10.1002\/14651858.CD009913.pub2-BIB0009|cit9","first-page":"95","article-title":"Fifth tuberculosis association of India: short course chemotherapy trial","volume":"36","author":"Research Committee of the Tuberculosis Association of India","year":"1989","journal-title":"Indian Journal of Tuberculosis"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0010|cit10","first-page":"22","article-title":"Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis","volume":"(11)","author":"Semenova","year":"2003","journal-title":"Problemy Tuberkuleza i Bolezne\u012d Legkikh"},{"issue":"11","key":"10.1002\/14651858.CD009913.pub2-BIB0011|cit11","first-page":"1029","article-title":"Fixed-dose combination chemotherapy (Rifater\/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up","volume":"6","author":"Su","year":"2002","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"1-3","key":"10.1002\/14651858.CD009913.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1472-9792(02)00053-7","article-title":"Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia","volume":"83","author":"Gravendeel","year":"2003","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1002\/14651858.CD009913.pub2-BIB0013|cit13","first-page":"174","article-title":"Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia?","volume":"12","author":"Suryanto","year":"2008","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD009913.pub2-BIB0014|cit14","first-page":"707","article-title":"Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service\/British Medical Research Council","volume":"143","author":"Anonymous","year":"1991","journal-title":"American Review and Respiratory Disease"},{"issue":"2","key":"10.1002\/14651858.CD009913.pub2-BIB0015|cit15","first-page":"126","article-title":"Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report","volume":"3","author":"Teo","year":"1999","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"6","key":"10.1002\/14651858.CD009913.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.6061\/clinics\/2015(06)08","article-title":"Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment","volume":"70","author":"Wu","year":"2015","journal-title":"Clinics (S\u00e3o Paulo)"},{"issue":"2","key":"10.1002\/14651858.CD009913.pub2-BIB0017|cit17","first-page":"185","article-title":"Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients","volume":"21","author":"Zaka-Ur-Rehman","year":"2008","journal-title":"Pakistan Journal of Pharmaceutical Sciences"},{"issue":"11","key":"10.1002\/14651858.CD009913.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0011-393X(96)80018-X","article-title":"Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis","volume":"57","author":"Zhang","year":"1996","journal-title":"Current Therapeutic Research"},{"issue":"11","key":"10.1002\/14651858.CD009913.pub2-BIB0019|cit19","first-page":"645","article-title":"Controlled clinical study on efficacy of fixed-dose compounds rifater\/rifinah in antituberculous chemotherapy","volume":"21","author":"Zhu","year":"1998","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Disease]"},{"issue":"10","key":"10.1002\/14651858.CD009913.pub2-BIB0020|cit20","first-page":"299","article-title":"Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years","volume":"119","author":"Br\u00e4ndli","year":"1989","journal-title":"Schweizerische Medizinische Wochenschrift"},{"issue":"25","key":"10.1002\/14651858.CD009913.pub2-BIB0021|cit21","first-page":"1300","article-title":"Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide","volume":"123","author":"Br\u00e4ndli","year":"1993","journal-title":"Schweizerische Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Chu N Gao M Ma L Controlled clinical study on efficacy of national fixed-dose compounds in antituberculosis chemotherapy. Respirology. Proceedings of the 9th Congress of the Asian Pacific Society of Respirology; 2004 Dec 10-13; Hong Kong Hong Kong 2004 72","DOI":"10.1111\/j.1440-1843.2004.00673.x"},{"issue":"8","key":"10.1002\/14651858.CD009913.pub2-BIB0023|cit23","first-page":"390","article-title":"Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet","volume":"77","author":"Cowie","year":"1990","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0024|cit24","first-page":"37","article-title":"Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis","volume":"47","author":"Dubra","year":"1972","journal-title":"Bulletin of the International Union against Tuberculosis and Lung Disease"},{"issue":"1","key":"10.1002\/14651858.CD009913.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/S1806-37132013000100011","article-title":"Clinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goi\u00e2nia, Brazil","volume":"39","author":"Ferreira","year":"2013","journal-title":"Jornal Brasileiro de Pneumologia [Brazilian Journal of Pulmonology]"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0026|cit26","first-page":"155","article-title":"A comparative community-based therapy trial with single combination product (Rifater-80)","volume":"2","author":"Glatthaar","year":"1991","journal-title":"CHASA; Journal of Comprehensive Health"},{"issue":"11","key":"10.1002\/14651858.CD009913.pub2-BIB0027|cit27","first-page":"717","article-title":"A comparison of the therapeutic efficacy of two drug combinations in cases of previously untreated open tuberculosis","volume":"32","author":"Gonz\u00e1lez Montaner","year":"1978","journal-title":"Praxis und Klinik der Pneumologie"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0028|cit28","unstructured":"Herman N Aditama TY Ikhsan M Comparison of antituberculosis drugs between fixed dose combination and combipack for new cases of pulmonary tuberculosis in community health centres Respirology. Proceedings of the 12th Congress of the Asian Pacific Society of Respirology 2007 A238"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD009913.pub2-BIB0029|cit29","first-page":"700","article-title":"Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service\/British Medical Research Council","volume":"143","author":"Anonymous","year":"1991","journal-title":"The American Review of Respiratory Disease"},{"issue":"6","key":"10.1002\/14651858.CD009913.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1164\/ajrccm\/140.6.1618","article-title":"Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy","volume":"140","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1989","journal-title":"The American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0031|cit31","unstructured":"ISRCTN95204603 Comparison of four Fixed Dose Combinations versus standard treatment with separate anti-TB drugs for treatment of pulmonary tuberculosis http:\/\/www.controlled-trials.com\/ISRCTN95204603"},{"issue":"6","key":"10.1002\/14651858.CD009913.pub2-BIB0032|cit32","first-page":"325","article-title":"Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town","volume":"84","author":"Macnab","year":"1994","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1745-6215-13-61","article-title":"A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project","volume":"13","author":"Merle","year":"2012","journal-title":"Trials"},{"issue":"6","key":"10.1002\/14651858.CD009913.pub2-BIB0034|cit34","first-page":"298","article-title":"A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up","volume":"78","author":"Punnotok","year":"1995","journal-title":"Journal of the Medical Association of Thailand"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0035|cit35","unstructured":"Soehardiman D Soepandi P Nawas A Comparison of Antituberculosis Drugs Between Fixed Dose Combinationand Combipack for New Cases of Pulmonary Tuberculosis in Persahabatan Hospital Respirology. Proceedings of the 12th Congress of the Asian Pacific Society of Respirology 2007 A237"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0036|cit36","first-page":"21","article-title":"Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms","volume":"(5)","author":"Sokolova","year":"1993","journal-title":"Problemy tuberkuleza"},{"issue":"10","key":"10.1002\/14651858.CD009913.pub2-BIB0037|cit37","first-page":"690","article-title":"Randomized control study on domestic fixed-dose combinations in the initial treatment of smears positive tuberculosis","volume":"27","author":"Xu","year":"2004","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi [Chinese Jjournal of Tuberculosis and Respiratory Diseases]"},{"issue":"2","key":"10.1002\/14651858.CD009913.pub2-BIB0038|cit38","first-page":"180","article-title":"Curative effect of fixed-dose anti-tuberculosis combinations in primary treatment of tuberculosis","volume":"29","author":"Liang","year":"2007","journal-title":"Chinese Journal of Anti-tuberculosis Association"},{"issue":"5","key":"10.1002\/14651858.CD009913.pub2-BIB0039|cit39","first-page":"21","article-title":"Feasibility study of domestic four-drug fixed-dose combination under DOTS as initial treatment in patients with smear positive pulmonary tuberculosis","volume":"61","author":"Ma","year":"2010","journal-title":"Chinese Journal of Anti-tuberculosis Association"},{"issue":"3","key":"10.1002\/14651858.CD009913.pub2-BIB0040|cit40","first-page":"122","article-title":"Randomized control study on domestic 4FDC\/2FDC combinations in initial treatment of smear positive tuberculosis patients","volume":"15","author":"Zhao","year":"2007","journal-title":"Parastosis and Infectious Disease"},{"issue":"5","key":"10.1002\/14651858.CD009913.pub2-BIB0041|cit41","first-page":"320","article-title":"Controlled clinical study on efficacy of fixed-dose compounds rifinah in anti-tuberculosis chemotherapy: results of two-year follow-up","volume":"48","author":"Zhu","year":"2000","journal-title":"Tuberculosis and Thoracic Tumor"},{"issue":"3","key":"10.1002\/14651858.CD009913.pub2-BIB0042|cit42","first-page":"209","article-title":"A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment","volume":"7","author":"Agounitestane","year":"1990","journal-title":"Revue des Maladies Respiratoires"},{"issue":"10","key":"10.1002\/14651858.CD009913.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5414\/CPP40474","article-title":"Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations","volume":"40","author":"Agrawal","year":"2002","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009913.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1183\/09031936.00180612","article-title":"Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis","volume":"42","author":"Albanna","year":"2013","journal-title":"The European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD009913.pub2-BIB0045|cit45","first-page":"59","article-title":"Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis","volume":"6","author":"Bellabas","year":"1989","journal-title":"Revue des Maladies Respiratoires"},{"issue":"1","key":"10.1002\/14651858.CD009913.pub2-BIB0046|cit46","first-page":"61","article-title":"The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis","volume":"79","author":"Blomberg","year":"2001","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0047|cit47","volume-title":"Treatment of Tuberculosis","volume":"MMWR 52[RR-11]","author":"Centers for Disease Control and Prevention","year":"2003"},{"issue":"12","key":"10.1002\/14651858.CD009913.pub2-BIB0048|cit48","first-page":"935","article-title":"Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review","volume":"82","author":"Connor","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"issue":"1-3","key":"10.1002\/14651858.CD009913.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1472-9792(02)00053-7","article-title":"Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia","volume":"83","author":"Gravendeel","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0050|cit50","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0051|cit51","volume-title":"International Standards for Tuberculosis Care (ISTC)","author":"TB CARE","year":"2014"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0052|cit52","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0053|cit53","volume-title":"Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Clinical Guidelines, CG33","author":"National Collaborating Centre for Chronic Conditions","year":"2006"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0054|cit54","volume-title":"Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control","author":"National Collaborating Centre for Chronic Conditions and Centre for Clinical Practice at National Institute for Health and Clinical Excellence","year":"2011"},{"issue":"10","key":"10.1002\/14651858.CD009913.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.5588\/ijtld.14.0281","article-title":"Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis","volume":"18","author":"Nunn","year":"2014","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0056|cit56","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0057|cit57","volume-title":"Interventions for Tuberculosis Control and Elimination","author":"Rieder","year":"2002"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD009913.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/ajrccm\/143.4_Pt_1.707","article-title":"Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis","volume":"143","author":"Singapore Tuberculosis Service\/British Medical Research Council","year":"1991","journal-title":"American Review of Respiratory Disease"},{"issue":"6","key":"10.1002\/14651858.CD009913.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"746","DOI":"10.5588\/ijtld.10.0094","article-title":"Implications of the current tuberculosis treatment landscape for future regimen change","volume":"15","author":"Wells","year":"2011","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0060|cit60","unstructured":"World Health Organization Operational guide for National Tuberculosis Control Programmes on the introduction and use of fixed-dose combination drugs. WHO\/CDS\/TB\/2002.308 http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js4872e\/"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0061|cit61","unstructured":"World Health Organization Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. September 2009 http:\/\/www.who.int\/tb\/challenges\/interim_paediatric_fdc_dosing_instructions_sept09.pdf"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0062|cit62","volume-title":"Guidelines for treatment of tuberculosis. WHO\/HTM\/TB\/2009.420","author":"World Health Organization","year":"2010"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0063|cit63","volume-title":"WHO Model List of Essential Medicines","author":"World Health Organization","year":"2011"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0064|cit64","unstructured":"World Health Organization Definitions and reporting framework for tuberculosis \u2014 2013 revision (updated December 2014) http:\/\/apps.who.int\/iris\/bitstream\/10665\/79199\/1\/9789241505345_eng.pdf"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0065|cit65","volume-title":"Guidance for national tuberculosis programmes on the management of tuberculosis in children","author":"World Health Organization","year":"2014"},{"key":"10.1002\/14651858.CD009913.pub2-BIB0066|cit66","volume-title":"Global Tuberculosis Report 2015","author":"World Health Organization","year":"2015"},{"issue":"2","key":"10.1002\/14651858.CD009913.pub2-BIB0067|cit67","first-page":"379","article-title":"Side effects of tuberculosis treatment with fixed-dose combinations","volume":"29","author":"Zhang","year":"2015","journal-title":"Journal of Biological Regulators and Homeostatic Agents"},{"issue":"10","key":"10.1002\/14651858.CD009913.pub2-BIB0068|cit68","first-page":"824","article-title":"Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules","volume":"2","author":"Zwolska","year":"1998","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"issue":"7","key":"10.1002\/14651858.CD009913.pub2-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009913","article-title":"Fixed-dose combinations of drugs versus single drug formulations for treating pulmonary tuberculosis","author":"Gallardo","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009913.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T03:27:35Z","timestamp":1715138855000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009913.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009913.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,17]]}}}